Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
US11279711B2 · kind B2 · utility
3Cited by
29References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2020 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Apr 18, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.